涂康生 副研究员
研究领域（方向）
1.肝胆肿瘤发生发展的分子机制及转化研究
2.肿瘤微环境
个人及工作简历
西安交通大学第一附属医院肝胆外科副研究员，医学博士，博士生导师，美国明尼苏达大学博士后研究员，美国梅奥医学中心联陪博士，陕西省杰出青年科学基金获得者，陕西省中青年科技创新领军人才，陕西省青年科技新星。主持国家自然科学基金3项以及省部级（重大）项目8项，以第一/通讯作者在Gastroenterology、Hepatology、Mol Ther、ACS Nano等期刊发表SCI论文40余篇，其中IF>10论文10余篇。参与完成省科技进步奖二等奖2项，获陕西省优秀博士学位论文、陕西省自然科学优秀学术论文二等奖，被提名“树兰医学青年奖”。担任中国抗癌协会肿瘤标志专业委员会青年创新联盟委员、陕西省抗癌协会临床肿瘤大数据应用专业委员会常委、陕西省抗癌协会转化医学专业委员会常委和陕西省国际医学交流促进会肝脏肿瘤MDT专业委员会常委以及J Clin Transl Hepatol、Mil Med Res、中华肿瘤防治杂志和中国普通外科杂志等专业期刊（青年）编委。入选中国专家普通外科领域和肝病科领域学术影响力百强榜（2021）和医学领域全球顶尖前10万科学家排名（2022）。
科研项目
1.国家自然科学基金面上项目，82373172，基质硬度微环境中去泛素化酶USP40调控p300促进肝星状细胞活化的机制研究，2024/01-2027/12，49万元
2.国家自然科学基金面上项目，81773123，肝星状细胞在细胞外基质高硬度微环境中活化并分泌COMP促进肝细胞癌进展的机制研究，2018/01-2021/12，60万元
3.国家自然科学基金青年项目，81402039，Fbxw7通过泛素化蛋白酶解YAP蛋白诱导肝癌细胞凋亡和生长阻滞，2015/01-2017/12，23万元
4.陕西省自然科学基础研究计划杰出青年科学基金项目，2020JC-36，肿瘤微环境与转移，2020/01-2022/12，30万元
5.浙江省自然科学基金华东医药联合基金重大项目，LHDMD23H300002，去泛素化酶USP40作为抗肝癌药物新靶标的可行性及机制研究，2023/01-2025/12，100万元
代表性论文
［1］X. Geng, X. Du, W. Wang, C. Zhang, X. Liu, Y. Qu, M. Zhao, W. Li, M. Zhang,K. Tu*, Y.Q. Li*, Confined Cascade Metabolic Reprogramming Nanoreactor for Targeted Alcohol Detoxification and Alcoholic Liver Injury Management, ACS Nano, 17(8) (2023)7443-7455.
［2］T. Chen, L. Wang, C. Chen, R. Li, N. Zhu, R. Liu, Y. Niu, Z. Xiao, H. Liu, Q. Liu*,K. Tu*, HIF-1alpha-activated TMEM237 promotes hepatocellular carcinoma progression via the NPHP1/Pyk2/ERK pathway, Cell Mol Life Sci, 80(5) (2023) 120.
［3］X. Yan, L. Meng, X. Zhang, Z. Deng, B. Gao, Y. Zhang, M. Yang, Y. Ma,K. Tu*, M. Zhang*, Q. Xu*, Reactive oxygen species-responsive nanocarrier ameliorates murine colitis by intervening colonic innate and adaptive immune responses, Mol Ther 31(5) (2023)1383-1401.
［4］Y. Zhang, W. Gao, Y. Ma, L. Cheng, L. Zhang, Q. Liu, J. Chen, Y. Zhao,K. Tu*, M. Zhang*, C. Liu*, Integrating Pt nanoparticles with carbon nanodots to achieve robust cascade superoxide dismutase-catalase nanozyme for antioxidant therapy, Nano Today 49 (2023) 101768
［5］Y. Cao, K. Cheng, M. Yang, Z. Deng, Y. Ma, X. Yan, Y. Zhang, Z. Jia, J. Wang,K. Tu*, J. Liang*, M. Zhang*, Orally administration of cerium oxide nanozyme for computed tomography imaging and anti-inflammatory/anti-fibrotic therapy of inflammatory bowel disease, J Nanobiotechnology 21(1) (2023) 21.
［6］X. Du, M. Zhang, H. Zhou, W. Wang, C. Zhang, L. Zhang, Y. Qu, W. Li*, X. Liu, M. Zhao,K. Tu*, Y.Q. Li*, Decoy Nanozymes Enable Multitarget Blockade of Proinflammatory Cascades for the Treatment of Multi-Drug-Resistant Bacterial Sepsis, Research (Wash D C) 2022 (2022) 9767643.
［7］C. Liu, X. Yan, Y. Zhang, M. Yang, Y. Ma, Q. Xu*,K. Tu*, M. Zhang*, Oral administration of turmeric-derived exosome-like nanovesicles with anti-inflammatory and pro-resolving bioactions for murine colitis therapy, J Nanobiotechnology 20(1) (2022) 206.
［8］X. Yan, C. Yang, M. Yang, Y. Ma, Y. Zhang, C. Liu, Q. Xu*,K. Tu*, M. Zhang*, All-in-one theranostic nano-platform based on polymer nanoparticles for BRET/FRET-initiated bioluminescence imaging and synergistically anti-inflammatory therapy for ulcerative colitis, J Nanobiotechnology 20(1) (2022) 99.
［9］T. Chen, R. Liu, Y. Niu, H. Mo, H. Wang, Y. Lu, L. Wang, L. Sun, Y. Wang,K. Tu*, Q. Liu*, HIF-1alpha-activated long non-coding RNA KDM4A-AS1 promotes hepatocellular carcinoma progression via the miR-411-5p/KPNA2/AKT pathway, Cell Death Dis 12(12) (2021) 1152.
［10］B. Yao, Y. Li, T. Chen, Y. Niu, Y. Wang, Y. Yang, X. Wei, Q. Liu*,K. Tu*, Hypoxia-induced cofilin 1 promotes hepatocellular carcinoma progression by regulating the PLD1/AKT pathway, Clin Transl Med 11(3) (2021) e366.
［11］L. Wang, L. Sun, R. Liu, H. Mo, Y. Niu, T. Chen, Y. Wang, S. Han,K. Tu*, Q. Liu*, Long non-coding RNA MAPKAPK5-AS1/PLAGL2/HIF-1alpha signaling loop promotes hepatocellular carcinoma progression, J Exp Clin Cancer Res 40(1) (2021) 72.
［12］L. Sun, L. Wang, T. Chen, Y. Shi, B. Yao, Z. Liu, Y. Wang, Q. Li, R. Liu, Y. Niu,K. Tu*, Q. Liu*, LncRNA RUNX1-IT1 which is downregulated by hypoxia-driven histone deacetylase 3 represses proliferation and cancer stem-like properties in hepatocellular carcinoma cells, Cell Death Dis 11(2) (2020) 95.
［13］L. Sun, Y. Wang, L. Wang, B. Yao, T. Chen, Q. Li, Z. Liu, R. Liu, Y. Niu, T. Song, Q. Liu*,K. Tu*, Resolvin D1 prevents epithelial-mesenchymal transition and reduces the stemness features of hepatocellular carcinoma by inhibiting paracrine of cancer-associated fibroblast-derived COMP, J Exp Clin Cancer Res 38(1) (2019) 170.
［14］Y. Wang, L. Yang, T. Chen, X. Liu, Y. Guo, Q. Zhu, X. Tong, W. Yang, Q. Xu*, D. Huang*,K. Tu*, A novel lncRNA MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by targeting miR-194-5p/FOXA1 axis, Mol Cancer 18(1) (2019) 28.
［15］Q. Li, C. Wang, Y. Wang, L. Sun, Z. Liu, L. Wang, T. Song, Y. Yao, Q. Liu*,K. Tu*, HSCs-derived COMP drives hepatocellular carcinoma progression by activating MEK/ERK and PI3K/AKT signaling pathways, J Exp Clin Cancer Res 37(1) (2018) 231.
［16］C. Dou#, Z. Liu#,K. Tu#, H. Zhang, C. Chen, U. Yaqoob, Y. Wang, J. Wen, J. van Deursen, D. Sicard, D. Tschumperlin, H. Zou, W.C. Huang, R. Urrutia, V.H. Shah, N. Kang, P300 Acetyltransferase Mediates Stiffness-Induced Activation of Hepatic Stellate Cells Into Tumor-Promoting Myofibroblasts, Gastroenterology 154(8) (2018) 2209-2221 e14.
［17］Q. Xu, J. Tu, C. Dou, J. Zhang, L. Yang, X. Liu, K. Lei, Z. Liu, Y. Wang, L. Li, H. Bao, J. Wang,K. Tu*, HSP90 promotes cell glycolysis, proliferation and inhibits apoptosis by regulating PKM2 abundance via Thr-328 phosphorylation in hepatocellular carcinoma, Mol Cancer 16(1) (2017) 178.
［18］C. Dou, X. Zheng, Q. Liu,K. Tu*, Is the regulatory effect of PCAF and sirtuin 7 on phosphoglycerate kinase 1 acetylation a universal mechanism underlying hepatocellular carcinoma progression?, Hepatology 66(5) (2017) 1699-1700.
［19］Q. Li, Z. Liu, M. Xu, Y. Xue, B. Yao, C. Dou, Y. Jia, Y. Wang,K. Tu*, X. Zheng*, Y. Yao*, PCAF inhibits hepatocellular carcinoma metastasis by inhibition of epithelial-mesenchymal transition by targeting Gli-1, Cancer Lett 375(1) (2016) 190-198.
［20］K. Tu, J. Li, V.K. Verma, C. Liu, D.D. Billadeau, G. Lamprecht, X. Xiang, L. Guo, R. Dhanasekaran, L.R. Roberts, V.H. Shah, N. Kang, Vasodilator-stimulated phosphoprotein promotes activation of hepatic stellate cells by regulating Rab11-dependent plasma membrane targeting of transforming growth factor beta receptors, Hepatology 61(1) (2015) 361-74.
科研获奖：
1.肝胰恶性肿瘤精准诊疗创新技术的基础研究及临床推广应用，浙江省人民政府，科技进步，省部二等奖，2022（黄东胜;许秋然;涂康生;金巍巍;牟一平;张成武;窦常伟;牟晓洲;胡晓歌）
2.肝癌创新诊疗的基础和临床应用研究，黄东胜；许秋然；张成武；张建宾；牟晓洲；涂康生；杨柳；窦常伟；吴国清，浙江省人民政府,科技进步,省部二等奖, 2020
联系方式
电子邮箱：tks0912@foxmail.com; tu.kangsheng@xjtu.edu.cn
联系电话：18049682029
联系地址：陕西省西安市雁塔西路277号
